Cover Image

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

Adoptive cellular therapy using chimeric antigen receptor T-cell (CART) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent p...

Full description

Saved in:
Bibliographic Details
Main Authors: Moreau, Philippe (Author) , Goldschmidt, Hartmut (Author)
Format: Article (Journal)
Language:English
Published: August 22, 2019
In: Haematologica
Year: 2019, Volume: 104, Issue: 12, Pages: 2358-2360
ISSN:1592-8721
DOI:10.3324/haematol.2019.224204
Online Access:Verlag, Volltext: https://doi.org/10.3324/haematol.2019.224204
Verlag: http://www.haematologica.org/content/104/12/2358
Get full text
Author Notes:Philippe Moreau, Pieter Sonneveld, Mario Boccadoro, Gordon Cook, Ma Victoria Mateos, Hareth Nahi, Hartmut Goldschmidt, Meletios A. Dimopoulos, Paulo Lucio, Joan Bladé, Michel Delforge, Roman Hajek, Heinz Ludwig, Thierry Facon, Jesus F. San Miguel and Hermann Einsele
Description
Summary:Adoptive cellular therapy using chimeric antigen receptor T-cell (CART) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent phase I / II trials show promising preliminary results in patients with MM progressing on proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies targeting CD38. CAR-T cell therapy is a potentially life-threatening strategy that can only be administered in experienced centers. For the moment, CAR-T cell therapy for MM is still experimental, but once this strategy has been approved in relapsed/refractory MM, it will become one of the most important indications for this therapy in Europe and world-wide. This manuscript proposes practical considerations for the use of CAR-T cell therapy in MM, and discusses several important issues for its future development.
Item Description:Gesehen am 15.01.2020
Physical Description:Online Resource
ISSN:1592-8721
DOI:10.3324/haematol.2019.224204

Similar Items